Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial
Open Access
- 18 June 2026
- journal article
- research article
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (5) , e70190
Abstract
Introduction: In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD). This study estimated the impact of type of OAT on pain among individuals with non‐heroin OUD. Methods: Using data from OPTIMA, a Canadian, randomised, 24‐week clinical trial comparing buprenorphine/naloxone (via take‐home doses) to methadone (via daily witnessed ingestion) for the treatment of non‐heroin OUD, we evaluated the impact of type of OAT on pain outcomes (measured by the Brief Pain Inventory) among participants with major pain at baseline. Results: Mean pain severity scores significantly decreased in both arms over 24 weeks (methadone 4.89–2.16, buprenorphine/naloxone 4.94–1.08). There was a time by arm interaction, suggesting better performance of buprenorphine/naloxone up to week 9, and methadone afterwards. Mean pain‐related function scores also significantly decreased over time (methadone 5.31–2.70, buprenorphine/naloxone 5.56–3.37), with no significant differences in overall scores between arms ( p = 0.675). Methadone was associated with higher odds of achieving both pain severity and pain‐related function response at week 24 (30% reduction in pain scores from baseline). Discussion and Conclusions: Among people with non‐heroin OUD initiating OAT, both methadone and buprenorphine/naloxone were associated with improvements in pain outcomes. However, methadone was associated with a higher likelihood of achieving pain severity and functional treatment response at week 24. These findings suggest the need to consider the type of OAT in the shared‐decision making process for people with non‐heroin OUD and comorbid pain.Keywords
Funding Information
- Canadian Institutes of Health Research (SMN‐139148)
- Canadian Institutes of Health Research (SMN‐139149)
- Canadian Institutes of Health Research (SMN‐139150)
- Canadian Institutes of Health Research (SMN‐139151)
This publication has 19 references indexed in Scilit:
- Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis PainJAMA, 2018
- Management of opioid use disorders: a national clinical practice guidelineCanadian Medical Association Journal, 2018
- Chronic pain and opioid misuse: a review of reviewsSubstance Abuse Treatment, Prevention, and Policy, 2017
- Guideline for opioid therapy and chronic noncancer painCanadian Medical Association Journal, 2017
- Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysisSubstance Abuse: Research and Treatment, 2015
- Complications of Long-Term Opioid Therapy for Management of Chronic Pain: the Paradox of Opioid-Induced HyperalgesiaJournal of Medical Toxicology, 2012
- Buprenorphine/NaloxoneDrugs, 2009
- Lifetime Comorbidity of DSM-IV Mood and Anxiety Disorders and Specific Drug Use DisordersThe Journal of Clinical Psychiatry, 2006
- d-Methadone Blocks Morphine Tolerance and N-Methyl-d-Aspartate-Induced HyperalgesiaThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Pain assessment: global use of the Brief Pain Inventory.1994